Development of Anticancer and Antiviral Drugs—2nd Edition

Dear Colleagues,

The editors are grateful to the many researchers who contributed to the success of the first volume of this issue (https://www.mdpi.com/journal/life/special_issues/Anticancer_and_Antiviral_Drugs). Therefore, we are very pleased to announce the second volume of our Special Issue "Development of Anticancer and Antiviral Drugs—2nd Edition".

Technological advances in recent years have enabled significant progress in the development of drugs for various diseases. However, cancer and viral diseases remain the two major categories of human diseases that require special attention in drug development. Many drugs have been approved for clinical use to treat cancers and viral infections, but none of these drugs are without toxicities or other side effects. In addition, the heterogeneity of cancers and drug resistance pose another problem for currently available drugs. Therefore, the continuous search for new candidates that can be used against cancer and viral diseases is necessary. In drug discovery, initial laboratory studies, such as the identification of novel druggable targets or potential lead molecules; screening; and evaluation of druggable properties of small molecule compounds, etc., play an important role. The advent of new molecular and cell biology techniques, bioinformatics, genomics, and other structural and functional methods have made possible new opportunities for anticancer and antiviral drug development. With this Special Issue, we aim to provide an overview of recent advances in cancer and antiviral drug development to a broader academic and scientific community.

We invite you to contribute original research articles, reviews, clinical study results, molecular and bioinformatics analyses, and structural and biophysical studies on anticancer and antiviral drug development that highlight new advances in the field.

We look forward to receiving your submission.

Prof. Dr. Ming-Hon Hou
Dr. Roshan Satange
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancers
• viral diseases
• drug development
• anticancer drugs
• antiviral drugs
• drug discovery
• structure-based drug designing
• molecular biology
• cell biology